BRAF mutations in iranian patients with papillary thyroid carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2521-2523

  Ranjbari, Nastran ^a   Almasi, Sara ^a   Mohammadi Asl, Javad ^a   Rahim, Fakher ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

BRAF proto; Oncogene; Papillary thyroid carcinoma; PCR; RFLP method; V600E mutation

Indexed keywords

EID: 84880285726     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2521     Document Type: Article

References (20)

1. Avruch J, Khokhlatchev A, Kyriakis JM, et al (2001). Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res, 56, 127-55.
2. Davies H, Bignell GR, Cox C, et al (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949-54.
3. Dralle H, Machens A (2008). Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab, 22, 971-87.
4. Durante C, Puxeddu E, Ferretti E, et al (2007). BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab, 92, 2840-3.
5. Jeong D, Jeong Y, Lee S, et al (2012). Detection of BRAF(V600E) mutations in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR: a comparison with direct sequencing. Korean J Pathol, 46, 61-67.
6. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004). Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J, 45, 818-21.
7. Kimura ET, Nikiforova MN, Zhu Z, et al (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63, 1454-7.
8. Lalami Y, Awada A (2011). Recurrent thyroid cancer: a molecular-based therapeutic breakthrough. Curr Opin Oncol. 23, 235-40.
9. Li X, Abdel-Mageed AB, Kandil E (2012). BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med, 5, 310-5.
10. Mercer KE, Pritchard CA (2003). Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta, 1653, 25-40.
11. Meyerhardt JA, Mayer RJ (2005). Systemic therapy for colorectal cancer. N Engl J Med, 352, 476-487.
12. Pakneshan S, Salajegheh A, Smith RA, Lam AK (2013). Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013 Apr 16 [PMID: 23594689].
13. Peyssonnaux C, Eychène A (2001). The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell, 93, 53-62.
14. Sithanandam G, Druck T, Cannizzaro LA, et al (1992). B-raf and a B-raf pseudogene are located on 7q in man. Oncogene, 7, 795-9.
15. Sithanandam G, Kolch W, Duh FM, Rapp UR (1990). Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene, 5, 1775-80.
16. Soares P, Trovisco V, Rocha AS, et al (2003). BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 22, 4578-80.
17. Takahashi K, Eguchi H, Arihiro K, et al (2007). The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog, 46, 242-8.
18. Xing MW, Tufano WH, Cohen RP, et al (2005). BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab, 90, 6373-9.
19. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA (2003). High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res, 63, 4561-7.
20. Yoon JH, Kim EK, Moon HJ, Kwak JY (2013) Is follow-up BRAF (V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis?. PLoS One, 8, 58592.